Onyx invests in continuous flow following API demand

By Fiona BARRY

- Last updated on GMT

Onyx invests in continuous flow following API demand
UK API-maker and contract research organisation (CRO) Onyx Scientific is installing equipment for continuous flow manufacturing to offer customers an alternative to batch manufacturing.

Denise Bowser, Commercial Director, told in-Pharmatechnologist.com the company has spent £80,000 ($137,000) on equipment for its premises in Sunderland, northeast England citing customer demand for flexibility during process development.

Pharmaceutical clients ask for continuous flow during product R&D, she said, for “a wider range of conditions for certain experiments,​” particularly surrounding hazardous reactions. “For us it’s a good thing to have the technology to give the clients full availability.​”

She added that continuous flow would make better use of the company’s space, give quicker output, and provide greater flexibility in compound manufacturing.

Continuous flow manufacturing – a technique that aims to lower costs and waste by integrating all stages of production – is “a very small area,​” Bowser told us. The majority of Onyx’s API manufacturing will continue to be batch work, she said; “we’re just giving our clients further scope for developing using different techniques.​”

API investment

The equipment purchase comes as part of a wider investment initiative, with Onyx announcing it is increasing its GMP manufacturing capacity with extra vessels, following increased demand for GMP API manufacturing services for drug development.

The company reported a 45% rise in solid-state chemistry-related revenues last year, which it said was driven by early stage campaigns.

In May this year, it completed an API manufacturing deal for US firm Neuronascent,​ producing a 1kg consignment for use in the neurology company’s marketing authorisation submission to the US Food and Drug Administration.

As well as its Sunderland-based laboratories, Onyx has access to seven API sites in India for technology transfer, pilot-scale work, and manufacturing for Phase II through to commercial.

Related news

Show more

Related products

TCC TB – a new filler for direct compression

TCC TB – a new filler for direct compression

Jungbunzlauer | 09-Oct-2017 | Technical / White Paper

TCC TB is a tricalcium citrate tetrahydrate designed to function as a direct compression excipient. It combines exceptional compression characteristics,...

Steridose

Optimizing vessel geometry for mag drive agitators

Steridose, Inc | 14-Sep-2017 | Technical / White Paper

The performance of a bottom mount magnetically driven agitator (mag drive mixer) is heavily dependent on its relationship with the vessel’s geometry, baffles,...

Related suppliers